Table 3.
Comparison of Propensity Score–Matched Sample of Patients With Advanced-Stage Epithelial Ovarian Cancer Overall and Stratified According to Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines
| Characteristic | Overall | Adherent | Nonadherent | χ2 Test P |
|---|---|---|---|---|
| Total | 5,124 (100.0) | 2,562 (50.0) | 2,562 (50.0) | |
| Age at diagnosis (y) | ||||
| 66–69 | 1,263 (24.6) | 629 (49.8) | 634 (50.2) | |
| 70–74 | 1,597 (31.2) | 794 (49.7) | 803 (50.3) | |
| 75–79 | 1,450 (28.3) | 733 (50.6) | 717 (49.4) | .85 |
| 80–84 | 6,66 (13.0) | 338 (50.8) | 328 (49.2) | |
| 85 or older | 148 (2.9) | 69 (45.9) | 80 (54.1) | |
| Race or ethnicity | ||||
| White | 4,630 (90.4) | 2,307 (49.8) | 2,323 (50.2) | |
| Black | 238 (4.6) | 123 (51.7) | 115 (48.3) | |
| Asian or Pacific Islander | 97 (1.9) | 44 (45.4) | 53 (54.6) | .54 |
| Hispanic | 58 (1.1) | 31 (53.4) | 27 (46.6) | |
| Other or unknown | 101 (2.0) | 57 (56.4) | 44 (43.6) | |
| Socioeconomic status | ||||
| Quartile 1 (lowest) | 1,133 (22.1) | 578 (51.0) | 555 (49.0) | |
| Quartile 2 (low-middle) | 1,224 (23.9) | 610 (49.8) | 614 (50.2) | .87 |
| Quartile 3 (high-middle) | 1,327 (25.9) | 663 (50.0) | 664 (50.0) | |
| Quartile 4 (highest) | 1,440 (28.1) | 711 (49.4) | 729 (50.6) | |
| Charlson-Deyo score | ||||
| 0 | 3,399 (66.3) | 1,712 (50.4) | 1,687 (49.6) | |
| 1 | 1,096 (21.4) | 540 (49.3) | 556 (50.7) | .76 |
| 2 or greater | 629 (12.3) | 310 (49.3) | 319 (50.7) | |
| FIGO –AJCC stage | ||||
| IIIC | 2,761 (53.9) | 1,366 (49.5) | 1,395 (50.5) | .42 |
| IV | 2,363 (46.1) | 196 (50.6) | 1,167 (49.4) | |
| Tumor histology | ||||
| Serous | 3,281 (64.0) | 1,645 (50.1) | 1,636 (49.9) | |
| Mucinous | 93 (1.8) | 48 (51.6) | 45 (49.4) | |
| Endometrioid | 248 (4.8) | 124 (50.0) | 124 (50.0) | .99 |
| Clear cell | 84 (1.6) | 41 (48.8) | 43 (51.2) | |
| Adenocarcinoma, NOS | 603 (11.8) | 297 (49.3) | 306 (50.7) | |
| Other | 815 (15.9) | 407 (49.9) | 408 (50.1) | |
| Tumor differentiation | ||||
| Grade 1–2 | 742 (14.5) | 376 (50.7) | 358 (51.2) | |
| Grade 3 | 2,577 (50.3) | 1,306 (50.7) | 407 (51.4) | .55 |
| Grade 4 | 680 (13.3) | 338 (49.7) | 411 (49.4) | |
| Grade unknown | 1,125 (22.0) | 542 (48.2) | 1,386 (49.5) | |
| Tumor size (cm) | ||||
| Less than 5 | 699 (13.6) | 341 (48.8) | 358 (51.2) | |
| 5–10 | 792 (15.5) | 385 (48.6) | 407 (51.4) | .70 |
| Greater than 10 | 832 (16.2) | 421 (50.6) | 411 (49.4) | |
| Unknown | 2,801 (54.7) | 1,415 (50.5) | 1,386 (49.5) |
FIGO, International Federation of Gynecology and Obstetrics; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified. Data are n (%) unless otherwise specified.